Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 8Primary Myelofibrosis 7Leukemia, Lymphocytic, Chronic, B-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Solid Tumors 4Leukemia, Myeloid, Acute 4Neoplasm Metastasis 3Lymphoma 3Small Cell Lung Carcinoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 2Leukemia 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Solid Tumor 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoid Malignancy × navitoclax × Clear all
NCT00982566 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

AbbVie

Phase 1 Completed
37 enrolled
Other solid neoplasm

Lymphoid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡